ARTIVA BIOTHERAPEUTICS INC (ARTV)
Health Care · Cell-based immunotherapy · NASDAQ
Artiva Biotherapeutics develops allogeneic natural killer cell immunotherapies for cancer, with its lead candidate AlloNK advancing through clinical trials.
What ARTIVA BIOTHERAPEUTICS INC does
Artiva Biotherapeutics is an early-stage biotechnology company developing AlloNK, an allogeneic natural killer cell immunotherapy for cancer indications. The company is advancing clinical trials for its lead product candidate and seeking regulatory approval for its manufacturing facility in San Diego, California. Artiva is focused on research, development, and eventual commercialization of cell-based immunotherapies.
Themes: ["cell immunotherapy"]
Fundamentals
- Price$9.41 as of 2026-07-09 close
- Market cap$457M as of 2026-07-10
- 1-year return+450.9% as of 2026-07-09 close
- Net margin-26045.0% as of 2026-07-10
- ROE-60.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta6.09 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial failure or delays in AlloNK development; ability to obtain FDA regulatory approval and timing for IND submissions and manufacturing facility authorization"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.